Evidence of cellular immune activation in children with opsoclonus-myoclonus: Cerebrospinal fluid neopterin

Journal of Child Neurology

Volumn 19, Issue 12, 2004, Pages 919-924

  Pranzatelli, Michael R ^a   Hyland, Keith ^b   Tate, Elizabeth D ^a   Arnold, Lauren A ^b   Allison, Tyler J ^a   Soori, Gamini S ^c  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; NEOPTERIN; TETRAHYDROBIOPTERIN;

ARTICLE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MYOCLONUS; NEUROBLASTOMA; OPSOCLONUS; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

EID: 13444257756     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738040190120201     Document Type: Article

References (23)

1. Kinsbourne M: Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962;25:221-276.
2. Solomon GE, Chutorian AM: Opsoclonus and occult neuroblastoma. N Engl J Med 1968;279:475-477.
3. Nishihara H, Toyoda Y, Tanaka Y, et al: Natural course of neuroblastoma detected by mass screening: A 5-year prospective study at a single institution. J Clin Oncol 2000;18:3012-3017.
4. Pranzatelli MR: The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1996;19:1-47.
5. Gennery AJ, Cant A, Forsyth RJ: Development of parainfectious opsoclonus in an infant by a non-humoral immune mechanism. Dev Med Child Neurol 2001;43:213-216.
6. Huber C, Fuchs D, Hansen A, et al: Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol 1983;130:1047-1050.
7. Ziegler J, Hamm U, Berndt J: Participation of pterins in the control of lymphocyte stimulation and lymphoblast proliferation. Cancer Res 1983;43:5356-5359.
8. Fuchs D, Weiss G, Reibnegger G, Wachter H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant disease. Crit Rev Clin Lab Sci 1992;29:307-341.
9. Wachter H, Fuchs D, Hansen A, et al: Neopterin as a marker for activation of cellular immunity: Immunological basis and clinical application. Adv Clin Chem 1989;27:81-141.
10. Millner MM, Franthal W, Thalhammer GH, et al: Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin Chem 1998;44:161-167.
11. Kern P, Rokos H, Dietrich M: Raised serum neopterin levels and imbalance of T lymphocyte subsets in viral diseases, acquired immunodeficiency and related lymphadenopathy syndrome. Biomed Pharmacother 1984;38:407-411.
12. Howells DW, Smith I, Hyland K: Dihydroneopterin and CNS infections. Lancet 1987;ii:686-687.
13. Tate ED, Pranzatelli MR, Huang YY, Kaplan R: An innovative approach to the problem of sedating children with opsoclonus-myoclonus syndrome: Effects on myoclonus and CSF monoamine metabolites, abstract. Ann Neurol 1994;36:543-544.
14. Howells DW, Smith I, Hyland K: Estimation of tetrahydrobiopterin and other pterins in cerebrospinal fluid using reverse-phase high performance liquid chromatography. J Chromatogr 1986;381: 285-294.
15. Pranzatelli MR, Tate ED, Galvan I, Wheeler A: A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus. Clin Neuropharmacol 2001;24:352-357.
16. Pranzatelli MR, Huang Y, Tate E, et al: Effect of high dose corticotropin on cerebrospinal fluid monoaminergic neurotransmitters or metabolites in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov Disord 1998;13:522-528.
17. SAS Institute Inc.: SAS/STAT User's Guide, Version 8.2. Cary, NC, SAS Institute Inc., 2002.
18. Furukawa Y, Nishi K, Kondo T, et al: Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci 1992;111:65-72.
19. Hyland K, Surtees RAH, Heales SJH, et al: Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993;34:10-14.
20. Zaknun D, Zaknun J, Unsinn K, et al: Interferon gamma-induced formation of neopterin and degradation of tryptophan in cerebrospinal fluid of children with meningitis but not with febrile convulsions. Pteridines 1994;5:102-106.
21. Hagberg L: The clinical use of cerebrospinal fluid neopterin concentrations in central nervous system infections. Pteridines 1996;6:147-152.
22. Pranzatelli MR, Travelstead A, Tate ED, et al: B and T cell markers in pediatric opsoclonus-myoclonus-ataxia: Immunophenotyping of CSF and blood lymphocytes by flow cytometry, abstract. Ann Neurol 2002;52(Suppl 1):S123.
23. Pranzatelli MR, Huang Y, Tate E, et al: Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome. Ann Neurol 1995;37:189-197.